Use of L-ribozymes (which are capable of splitting L-RNA in a region of a target sequence) for preparing composition to treat undesired physiological secondary reactions due to administration of a therapeutic molecule containing L-RNA

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of L-ribozymes—a type of engineered molecule that can specifically split L-RNA sequences—for creating pharmaceutical compositions. These compositions are designed to counteract unwanted side effects caused by therapeutic molecules containing L-RNA, and to treat or prevent diseases related to the overexpression of certain genes by targeting their RNA.

Use CasesContent extracted from patent full text and abstract with AI.

• Treating patients experiencing adverse physiological reactions to therapies containing L-RNA molecules
• Preventing or reducing side effects during L-RNA-based therapeutic treatments
• Treating diseases associated with overexpression of endogenous genes by selectively targeting their RNA
• Developing safer and more targeted gene therapies using L-ribozymes
• Pharmaceutical development aimed at regulating gene expression at the RNA level

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a targeted method to reduce or eliminate unwanted side effects from RNA-based therapies
• Enables precise control over gene expression by splitting specific RNA sequences
• Improves the safety profile of L-RNA therapeutic molecules
• Versatile application in both treatment and prevention of gene overexpression-related diseases
• Potential to enhance the efficacy and tolerability of innovative gene therapies

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Use of L-ribozymes (which are capable of splitting L-RNA in a region of a target sequence of the L-RNA) for preparing a pharmaceutical composition to treat undesired physiological secondary reactions due to the administration of a therapeutic molecule containing L-RNA, is claimed. Independent claims are included for: (1) use of L-ribozymes for preparing a pharmaceutical composition for the treatment or prophylaxis of diseases, which are associated with the overexpression of at least one endogenous gene, where the L-ribozyme is capable of splitting a target sequence of a target-D-RNA coding for the endogenous gene; (2) the pharmaceutical composition comprising L-ribozyme for treating undesired physiological secondary reactions due to the administration of a therapeutic molecule containing L-RNA or for the treatment or prophylaxis of diseases, which are associated with the overexpression of at least one endogenous gene, where the L-ribozyme is capable of splitting a target sequence of a target-D-RNA coding for the endogenous gene; and (3) preparing the pharmaceutical composition, comprising generating a sequence from L-nucleotide and synthesizing, which is capable of splitting a predetermined sequence from L-ribonucleotide or D-ribonucleotide, where the L-ribozyme is prepared in pharmacological active dosage form for administration. ACTIVITY : Antidote. MECHANISM OF ACTION : None given.